Monitor stock price post-split to confirm it holds above $1.00 and avoids further delisting risk. The split is precautionary given the company already met the bid price condition, but the Nasdaq panel's ongoing compliance requirements bear watching.
Price Chart
Executive Summary
HCW Biologics announced a 1-for-6 reverse stock split effective June 30, 2026, to ensure compliance with Nasdaq's minimum bid price rule after receiving a panel decision letter on May 29, 2026. The split reduces outstanding shares from ~9.6M to ~1.6M and is a prophylactic measure as the stock already met the 20-day $1.00 requirement. The filing contains no financial data; the move aims to prevent automatic delisting.
Key Facts
- Reverse stock split ratio: 1-for-6, effective June 30, 2026 at 12:01 a.m. ET
- Outstanding shares pre-split: 9,581,079; post-split: ~1,596,849
- Authorized shares unchanged at 250,000,000
- Stock already had 28 consecutive trading days above $1.00 as of June 25, 2026
- Nasdaq Hearings Panel required compliance by July 29, 2026; any future noncompliance before Sep 22, 2026 triggers automatic delisting
Financial Impact
Reverse stock split reduces outstanding shares from 9,581,079 to approximately 1,596,849, with no change in authorized shares or par value. No fractional shares issued.
Risk Factors
- Stock may fail to maintain the $1.00 minimum bid price post-split, leading to delisting
- Reverse splits often attract selling pressure in the short term
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-030236 |
| Exhibit: ex99-1.htm | 0001493152-26-030236 |
| Exhibit: ex3-1.htm | 0001493152-26-030236 |
| Document: 0001493152-26-030236-index-headers.html | 0001493152-26-030236 |
| Document: 0001493152-26-030236-index.html | 0001493152-26-030236 |
| Document: 0001493152-26-030236.txt | 0001493152-26-030236 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | EFFECT | $1.26 | awaiting T+60 | — | $1.10 (+12.70%) |
Oct 2, 2026 24d ago | S-1 | $1.64 | awaiting T+60 | — | $1.10 (+32.93%) |
Oct 1, 2026 25d ago | DEF 14A | $1.69 | awaiting T+60 | — | $1.10 (+34.91%) |
Sep 24, 2026 4w ago | 8-K | $1.99 | awaiting T+60 | — | $1.10 (+44.72%) |
Aug 20, 2026 9w ago | S-1 | $2.12 | awaiting T+60 | — | $1.10 (−48.11%) |
Aug 14, 2026 10w ago | 8-K | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Aug 14, 2026 10w ago | Press Release | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Aug 14, 2026 10w ago | 10-Q/A | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Aug 14, 2026 10w ago | 8-K | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Jul 29, 2026 12w ago | Press Release | $2.58 $1.12 | ▲ +56.59% | ▲ +61.32% | $1.10 (+57.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers